Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

BERKELEY, US and MAINZ, Germany – December 16, 2024 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant […]